Acer Therapeutics Shares Outstanding vs. Cash Per Share

ACERDelisted Stock  USD 0.84  0.02  2.33%   
Based on Acer Therapeutics' profitability indicators, Acer Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Acer Therapeutics' ability to earn profits and add value for shareholders.
For Acer Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Acer Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Acer Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Acer Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Acer Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Please note, there is a significant difference between Acer Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acer Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acer Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Acer Therapeutics Cash Per Share vs. Shares Outstanding Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Acer Therapeutics's current stock value. Our valuation model uses many indicators to compare Acer Therapeutics value to that of its competitors to determine the firm's financial worth.
Acer Therapeutics is rated second in shares outstanding category among its peers. It is rated below average in cash per share category among its peers . The ratio of Shares Outstanding to Cash Per Share for Acer Therapeutics is about  26,883,187 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Acer Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Acer Cash Per Share vs. Shares Outstanding

Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Acer Therapeutics

Shares Outstanding

 = 

Public Shares

-

Repurchased

 = 
24.46 M
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Acer Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
0.91 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Acer Cash Per Share Comparison

Acer Therapeutics is currently under evaluation in cash per share category among its peers.

Acer Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Acer Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Acer Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Acer Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Acer Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. Acer Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.

Acer Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Acer Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Acer Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Acer Therapeutics' important profitability drivers and their relationship over time.

Use Acer Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acer Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acer Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Acer Therapeutics Pair Trading

Acer Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Acer Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acer Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acer Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acer Therapeutics to buy it.
The correlation of Acer Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acer Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acer Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acer Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Acer Therapeutics position

In addition to having Acer Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Disruptive Technologies Thematic Idea Now

Disruptive Technologies
Disruptive Technologies Theme
New or established technology companies and funds across multiple sectors that are involved in development or marketing of products or services that experience disruptive trends and that are at the forefront of discussions on Wall Street. The Disruptive Technologies theme has 64 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Disruptive Technologies Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Acer Stock

If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Commodity Directory
Find actively traded commodities issued by global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years